Ali Yilmaz1, Abdullah Topcu1, Cagdas Erdogan2, Barbaros Sahin3, Gulcin Abban4, Erdal Coskun5, Ayca Ozkul1. 1. Adnan Menderes University, Neurosurgery Department, Aydın, Turkey. 2. Pamukkale University, Neurology Department, Denizli, Turkey. 3. University Medicine Faculty, Animal Laboratory, Denizli, Turkey. 4. Pamukkale University Medicine Faculty, Histology and Embryology Department, Denizli, Turkey. 5. Pamukkale University, Medicine Faculty, Neurosurgery Department, Denizli, Turkey.
Abstract
AIM: There are many trials concerning peripheral nerve damage causes and treatment options. Unfortunately, nerve damage is still a major problem regarding health, social and economic issues. On this study, we used vascular graft and human cord blood derived stem cells to find an alternative treatment solution to this problem. MATERIAL AND METHODS: We used 21 female Wistar rats on our study. They were anesthetized with ketamine and we studied right hind limbs. On Group 1, we did a full layer cut on the right sciatic nerve. On Group 2, we did a full layer cut on the right sciatic nerve, and we covered synthetic vascular graft on cut area. On Group 3, we did a full layer cut on right sciatic nerve, and we covered the area with stem cell applied vascular graft. RESULTS: At the end of postoperative 8. weeks, we performed EMG on the rats. When we compared healthy and degenerated areas as a result of EMG, we found significant amplitude differences between the groups on healthy areas whereas there was no significant difference on degenerated areas between the groups. Then we re-opened the operated area again to reveal the sciatic nerve cut area, and we performed electron microscope evaluation. On the stem cell group, we observed that both the axon and the myelin sheet prevented degeneration. CONCLUSION: This study is a first on using synthetic vascular graft and cord blood derived CD34+ cells in peripheral nerve degeneration. On the tissues that were examined with electron microscope, we observed that CD34+ cells prevented both axonal and myelin sheath degeneration. Nerve tissue showed similar results to the control group, and the damage was minimal.
AIM: There are many trials concerning peripheral nerve damage causes and treatment options. Unfortunately, nerve damage is still a major problem regarding health, social and economic issues. On this study, we used vascular graft and human cord blood derived stem cells to find an alternative treatment solution to this problem. MATERIAL AND METHODS: We used 21 female Wistar rats on our study. They were anesthetized with ketamine and we studied right hind limbs. On Group 1, we did a full layer cut on the right sciatic nerve. On Group 2, we did a full layer cut on the right sciatic nerve, and we covered synthetic vascular graft on cut area. On Group 3, we did a full layer cut on right sciatic nerve, and we covered the area with stem cell applied vascular graft. RESULTS: At the end of postoperative 8. weeks, we performed EMG on the rats. When we compared healthy and degenerated areas as a result of EMG, we found significant amplitude differences between the groups on healthy areas whereas there was no significant difference on degenerated areas between the groups. Then we re-opened the operated area again to reveal the sciatic nerve cut area, and we performed electron microscope evaluation. On the stem cell group, we observed that both the axon and the myelin sheet prevented degeneration. CONCLUSION: This study is a first on using synthetic vascular graft and cord blood derived CD34+ cells in peripheral nerve degeneration. On the tissues that were examined with electron microscope, we observed that CD34+ cells prevented both axonal and myelin sheath degeneration. Nerve tissue showed similar results to the control group, and the damage was minimal.
Authors: Paul R Sanberg; Alison E Willing; Svitlana Garbuzova-Davis; Samuel Saporta; Guoqing Liu; Cyndy Davis Sanberg; Paula C Bickford; Stephen K Klasko; Nagwa S El-Badri Journal: Ann N Y Acad Sci Date: 2005-05 Impact factor: 5.691
Authors: Paul J Kingham; Mallappa K Kolar; Liudmila N Novikova; Lev N Novikov; Mikael Wiberg Journal: Stem Cells Dev Date: 2013-11-22 Impact factor: 3.272